All In Biotech

Drug Trial Radar · NCT01867125

A Study of Lebrikizumab in Participants With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and a Second Controller Medication

A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and a Second Controller Medication

Last checked: Nov 19, 2026Latest source record: Jul 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,081 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,081

Actual

Start

Jul 25, 2013

Primary completion

Dec 28, 2016

Study completion Dec 28, 2016

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Jun 3, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This randomized, multicenter, double-blind, placebo-controlled, parallel-group study will evaluate the efficacy and safety of lebrikizumab in participants with asthma whose disease remains uncontrolled despite daily treatment with inhaled corticosteroid (ICS) therapy and at least one second controller medication. Participants will be randomized in 1:1:1 ratio to receive double-blind treatment with either lebrikizumab ("high" or "low") or placebo, administered subcutaneously (SC) every 4 weeks for 52 weeks, in addition to their standard-of-care therapy. This will be followed by a 52-week double-blind active treatment extension. During double-blind active treatment extension period, all participants will receive SC injection of lebrikizumab from Week 53 to Week 104. The anticipated time on study treatment is 104 weeks. After study treatment, all participants will complete a 20-week safety follow-up.

Conditions

  • Asthma

Interventions

  • LebrikizumabDrug

    Lebrikizumab will be administered as SC injection at 125 or 37.5 mg every 4 weeks, for 104 weeks.

  • PlaceboDrug

    Lebrikizumab matching placebo will be administered as SC injection every 4 weeks for 52 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adjusted Exacerbation Rate of Asthma During the 52-Week PCPTime frame: Baseline up to 52 weeks

Locations

181 sites in 26 countries. Site status is shown where the registry gives one.

  • Alabama Clinical Research Associates

    Pell City, Alabama

  • Desert Sun Clinical Research LLC

    Tucson, Arizona

  • Allianz Medical and Research Center

    Fountain Valley, California

  • Allergy & Asthma Medical Group & Research Center, Pc

    Long Beach, California

  • Allergy Medical Clinic

    Los Angeles, California

  • CA Allergy & Asthma Med Grp

    Los Angeles, California

  • North Bay Clinical Trials

    Napa, California

  • Choc Psf, Amc

    Orange, California

  • Advances in Medicine

    Rancho Mirage, California

  • Allergy Assoc Medical Group

    San Diego, California

  • Bensch Research Associates

    Stockton, California

  • IMMUNOe Research Centers

    Centennial, Colorado

  • Waterbury Pulmonary Associates

    Waterbury, Connecticut

  • St. Francis Sleep; Allergy & Lung Institute

    Clearwater, Florida

  • Suncoast Research Group LLC

    Miami, Florida

  • Emerald Coast Research Associates

    Panama City, Florida

  • Allergy & Asthma Diagnostic; Treatment Center

    Tallahassee, Florida

  • Florida Pulmonary Research Institute, LLC

    Winter Park, Florida

  • Atlanta Allergy & Asthma Clini

    Woodstock, Georgia

  • Northeast Medical Research Associates, Inc

    North Dartmouth, Massachusetts

  • Midwest Clinical Research LLC

    St Louis, Missouri

  • Montana Medical Research LLC

    Missoula, Montana

  • Heartland Clinical Research Inc.

    Omaha, Nebraska

  • Asthma & Allergy Center, P.C.

    Papillion, Nebraska

  • Allergy & Asthma Associates

    Las Vegas, Nevada

  • Allergy & Asthma Research of Nj, Inc

    Mount Laurel, New Jersey

  • Atlantic Research Center, LLC

    Ocean City, New Jersey

  • Princeton Center For Clinical Research

    Skillman, New Jersey

  • Montefiore Medical Center

    The Bronx, New York

  • Allergy & Asthma Center of NC

    High Point, North Carolina

  • PMG Research of Wilmington

    Wilmington, North Carolina

  • Asthma & Allergy Center

    Toledo, Ohio

  • Cor Clinical Research

    Oklahoma City, Oklahoma

  • Allergy & Asthma Research Grp

    Eugene, Oregon

  • Clinical Research Inst. of Southern Oregon, Pc

    Medford, Oregon

  • Allergy Associates Research Center LLC - CRN

    Portland, Oregon

  • Asthma Allergy Pulm Associates

    Philadelphia, Pennsylvania

  • Grand View Hospital; Clinical Research Department

    Sellersville, Pennsylvania

  • Asthma Allergy Phys of RI

    Lincoln, Rhode Island

  • ADAC Research PA

    Greenville, South Carolina

Showing 40 of 181 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.